The Detour Through Your Gut: What a 2026 Head-to-Head Trial Revealed About How NMN Reaches Your Blood

Chapter 1

Four Groups, Fourteen Days

Most people picture NMN making a short, straight trip: you swallow a capsule, it slips into your bloodstream, and your cells turn it into NAD+. A trial published in January 2026 suggests the real route is more interesting than that, and it starts with a result almost nobody expected.

A research team in Lausanne gave healthy adults one of three forms of vitamin B3, or a placebo, for two weeks. Two of the three forms roughly doubled the NAD+ in their blood. The third, and the simplest of them, did not lift it at all over those two weeks.

That odd result sent the researchers looking for clues: in the blood, in urine, in samples of gut bacteria grown in the lab, and in fresh blood kept in a dish. The trail those clues left points somewhere most of us never think about when we take NMN: the gut, and the bacteria that live there.

By the end of this article you will know what the trial compared, what doubled and what stayed flat, which footprints in the blood gave NMN's route away, what gut bacteria did with NMN in the lab, and what the human dose studies mean for how you take it. You will also know exactly where the evidence stops.

Section 1

A Trial With an Unexpected Loser

NAD+ is a molecule every cell uses to turn food into energy and to run its maintenance enzymes. Blood levels of NAD+ tend to be lower in older people, which is why so much research now asks a practical question: which precursor, swallowed as a supplement, actually raises it?

Three precursors dominate that research. Nicotinamide (often shortened to Nam) is the simplest form of vitamin B3 and the one found in many multivitamins. Nicotinamide riboside (NR) is a slightly larger molecule. Nicotinamide mononucleotide (NMN) is larger again and sits one step before NAD+ on the cell's main recycling road.

The Lausanne trial put all three side by side, which is rarer than you might think. Most studies test one precursor against a placebo, so comparisons between them usually rest on different people, different labs and different methods. Here, the same team used the same measurements on everyone.

Sixty-five healthy adults aged 18 to 50 completed the study and were included in the analysis. Their average age was about 35, and men and women were almost evenly split. Everyone took their supplement by mouth, once a day, with a standardised breakfast on the test days.

Four groups, one set of measurements: a rare like-for-like comparison of NAD+ precursors.

Section 2

What Doubled and What Stayed Flat

After 14 days, the NMN group's whole-blood NAD+ was 43.1 micromoles per litre higher than the placebo group's. The NR group's was 49.4 higher. In plain terms, both roughly doubled their blood NAD+ in two weeks.

The nicotinamide group showed something different. A few hours after a dose, there was a small, short-lived bump in some NAD+-related molecules, but after two weeks their blood NAD+ was not significantly different from placebo.

That is the anomaly at the heart of this story. Nicotinamide is the very molecule cells recycle into NAD+ on their main road. If NAD+ were simply a matter of supplying raw material to that road, nicotinamide should have done at least as well as the larger molecules. It did not.

Section 3

Why a Nutrition Company's Trial Is Worth Reading

We think you should know who ran this study. Most of the authors work for Nestlé Research or Nestlé Health Science, and Nestlé sells NR. A trial like this deserves the same careful reading we would give any company's research, including our own suppliers'.

That context makes one result particularly worth noticing. In a study run by a company that sells NR, NMN raised blood NAD+ by a similar amount. The two were close, NR slightly higher, and the paper reports both plainly.

The design also has limits we will keep coming back to. The trial was open-label, meaning participants knew which supplement they were taking. It lasted two weeks. And its volunteers were young and healthy, with an average age of about 35, so it tells us how these precursors behave in a young body, not necessarily in yours if you are 60.

None of that undoes the main finding. Blood NAD+ is measured in a lab, not reported by the participant, so knowing what you took is unlikely to change the number. But it is the reason this article treats the trial as a strong clue, not a final verdict.

Chapter 2

Following the Molecule

When a precursor doubles your blood NAD+, the obvious assumption is that it simply walked in through the front door. The researchers did not assume. They looked for the tracks it left behind.

Section 1

Footprints in the Blood

Every road into NAD+ leaves its own by-products, a bit like footprints that tell you which path someone took through fresh snow. Measure the right by-products and you can work out which road was busy.

After two weeks of NMN or NR, two telling footprints appeared. A molecule called NAAD rose in the blood, and a related molecule called NAR rose in the urine. Neither change appeared in the nicotinamide group.

Those two molecules matter because they do not belong to the cell's main recycling road. They are signatures of a second road into NAD+, one that starts from a different molecule altogether: nicotinic acid.

Section 2

Two Roads Into the Same Molecule

Your body has more than one way to build NAD+. Two of them matter for this story.

The first is the salvage road, the recycling route most cells use all day long. It turns nicotinamide into NMN, and NMN into NAD+. This is the road most people have in mind when they think about NMN: one step from NMN to NAD+, job done.

The second is the Preiss–Handler road, named after the two scientists who described it in the 1950s. It starts from nicotinic acid, another form of vitamin B3, and passes through NAAD on its way to NAD+.

So the footprints raised a fascinating possibility. Some of the NMN people swallowed seemed to be reaching NAD+ by way of nicotinic acid, on the second road, rather than simply walking up the first. Something had to be turning NMN into nicotinic acid. The question was what, and where.

Two roads, one destination: both end at NAD+.

Section 3

The Blood-Sample Surprise

To test what blood itself does with each precursor, the team added them to fresh whole blood from four donors and watched what happened over several hours in the lab.

The result was striking. NMN was broken down within about half an hour, and NR within about an hour, without raising the NAD+ signal in the blood cells. Nicotinic acid, by contrast, raised the NAD+ signal by about 170% over the same period.

In other words, at least in a dish, blood cells did far more with nicotinic acid than with NMN itself. That fits neatly with the footprints from the trial: if much of swallowed NMN arrives as something else, the something else may be doing a good deal of the work.

If you have read our earlier article on why NAD+ recycling in muscle slows with age, this adds a new layer. That story was about the cell's own recycling road. This one is about how a swallowed precursor may reach that cell in the first place.

The NMN in this article

Pure-NMN 500 mg · 60 Capsules

Each vegan pullulan capsule holds 500 mg of β-NMN, so two capsules give the 1,000 mg used in the 2026 trial. 60 capsules, a 30-day supply at that dose, or 60 days at one capsule a day.

Who it suits: adults who want plain NMN, taken by mouth, at the dose the head-to-head trial used, without measuring powder.

The trial used NMN for 14 days in healthy adults aged 18–50. It does not tell us how any one person will respond.

Add to cart · €69.95 →See full details

Or pass the Final Master Quiz below first: 4 out of 5 unlocks a private reader reward on this product.

🔒 LOCKED: EXCLUSIVE READER REWARD

There is a private, unadvertised reader reward waiting at the end of this article.

Read the next two chapters closely. Score at least 4 out of 5 on the Final Master Quiz at the bottom of the page and we will unlock a reward chosen for the reader who has just followed NMN on its whole journey, together with a private code that never appears on our public pages. Your reward code works from 1 to 15 November 2026.

The answers are all in the chapters ahead…

Chapter 3

Your Bacteria Join the Route

If something was turning NMN into nicotinic acid, the gut was the obvious suspect. It holds tens of trillions of bacteria, and many of them are very good at taking B3 molecules apart.

Section 1

The Fermentation Experiment

To see what gut bacteria do with these precursors, the team used a laboratory model of the colon. They took stool samples from donors, which carry each person's own mix of gut bacteria, and grew them with the precursor for up to 48 hours, sampling as they went.

With NR, the bacteria first cut it down to nicotinamide, and then converted nicotinamide into nicotinic acid, which built up and stayed high through the last day of the experiment. When the team repeated the experiment with NMN, they saw the same build-up of nicotinamide and then nicotinic acid.

That is exactly the missing link the footprints suggested. Bacteria can turn swallowed precursors into nicotinic acid, and nicotinic acid is the starting point of the second road into NAD+.

The bacteria also produced more short-chain fatty acids, molecules gut microbes make when they ferment food and that researchers study closely in gut health. It is an early observation from the lab, but an interesting one.

In a lab model of the colon, donor gut bacteria turned NMN into nicotinamide and then nicotinic acid.

Section 2

Older Guts Did It Too

A fair question is whether this only happens in young people. The gut community changes as we age, and the trial's volunteers had an average age of about 35.

So it is worth knowing who donated the bacteria for the NMN experiment: twelve healthy older adults, described in the paper as over 65 or over 70 in different sections. Their gut bacteria made the same conversion.

That does not mean every older gut behaves identically. It does mean the detour is not something only young microbes can make, which is reassuring for readers in their fifties, sixties and beyond.

Section 3

What We Still Don't Know

This is the part of the story where careful reading matters most, so here is everything the research does not yet tell us.

What we can say is this: the two-week rise in blood NAD+ is a measured human result, and the gut-bacteria route is the researchers' best current explanation for how much of it happens.

Chapter 4

What This Means for How You Take NMN

A route is only useful if it changes what you do. Here is what the human studies of NMN, read alongside the 2026 trial, suggest for the person who takes it every day.

Section 1

The Doses Behind the Trials

The Lausanne trial is not the only human study to raise blood NAD+ with NMN. Several randomised, placebo-controlled trials have now done it, across different ages and doses.

The 60-day trial is especially useful because it compared three doses directly. Blood NAD+ rose at every dose, with the highest levels in the 600 mg and 900 mg groups. Participants in those groups also walked further in a six-minute walking test, and NMN was well tolerated up to 900 mg a day for the full 60 days.

A later look back at the same trial's data (a post hoc analysis) found that people whose NAD+ rose more also tended to show small rises in some red-blood-cell measures. That is an association spotted after the fact, worth noting and not worth leaning on.

The 2023 study in 55- to 80-year-olds matters for older readers: it showed that pharmaceutical-grade NMN at 1,000 mg once or twice a day raised blood NAD+ in that age group within two weeks, and that very little NMN appeared unchanged in the urine.

Section 2

Plain Oral NMN Is What the Evidence Used

Look back at the table and one thing unites every row: the NMN was swallowed. Capsules or powder taken by mouth, at daily doses from 250 mg to 2,000 mg, raised blood NAD+ in each trial.

The 2026 findings give that a new meaning. If a large share of NMN's effect runs through the gut, then a capsule that reaches the gut intact and on schedule is not a compromise. It is the route the human evidence actually tested.

It also explains why the simplest-looking precursor is not necessarily the best one. Nicotinamide is cheap and familiar, yet over two weeks it did not raise blood NAD+ in this trial. Size and route seem to matter more than simplicity.

Two 500 mg capsules: the 1,000 mg daily dose used in the 2026 head-to-head trial.

Section 3

A Routine You Can Keep

If you take NMN, the practical lesson from these trials is less about tricks and more about consistency. The NAD+ rises were measured after daily intake for two weeks, eight weeks and twelve weeks, not after a single dose.

We will not tell you that one time of day or one trick beats another; none of these trials tested that. What they did test is plain NMN, swallowed daily, at known doses. That is a routine anyone can follow.

The NMN in this article

Pure-NMN 500 mg · 60 Capsules

500 mg β-NMN per capsule, 99.9% purity verified by independent ¹H-NMR analysis, in a vegan pullulan capsule with no other ingredients. Two capsules a day give 1,000 mg; one a day gives 500 mg.

Who it suits: adults who want to follow the oral, daily NMN routine used in the human trials, at a dose they can see on the label.

Human NMN trials so far are short (two weeks to three months) and measure blood NAD+; they do not show effects on lifespan.

Add to cart · €69.95 →See full details

Or pass the Final Master Quiz below first: 4 out of 5 unlocks a private reader reward on this product.

Complete Reference List

The head-to-head trial

Human NMN dose trials

Follow-up analysis